Sugi Predict

Sugi Predict / Targets / CCR3

CCR3

C-C chemokine receptor type 3 · P51677 · CCR3 on Sugi Atlas →

61,493 patent compounds predicted against CCR3, 35,380 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL179973 SCHEMBL179973 1.00 20/20
SCHEMBL179983 SCHEMBL179983 1.00 20/20
SCHEMBL180011 SCHEMBL180011 1.00 20/20
SCHEMBL180012 SCHEMBL180012 1.00 20/20
SCHEMBL180025 SCHEMBL180025 1.00 20/20
SCHEMBL180032 SCHEMBL180032 1.00 20/20
SCHEMBL180056 SCHEMBL180056 1.00 20/20
SCHEMBL180057 SCHEMBL180057 1.00 20/20
SCHEMBL180058 SCHEMBL180058 1.00 20/20
SCHEMBL180096 SCHEMBL180096 1.00 20/20
SCHEMBL180119 SCHEMBL180119 1.00 20/20
SCHEMBL180183 SCHEMBL180183 1.00 20/20
SCHEMBL180245 SCHEMBL180245 1.00 20/20
SCHEMBL180270 SCHEMBL180270 1.00 20/20
SCHEMBL180281 SCHEMBL180281 1.00 20/20
SCHEMBL180312 SCHEMBL180312 1.00 20/20
SCHEMBL180313 SCHEMBL180313 1.00 20/20
SCHEMBL180326 SCHEMBL180326 1.00 20/20
Water Water (SCHEMBL180418) 0.98 20/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL180178) 0.98 20/20

Clinical trials — most relevant to CCR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia PHASE3SUSPENDED
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation PHASE3SUSPENDED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
Aerosol Combination Therapy of All-trans Retinoic Acid and Isotretinoin as A Novel Treatment for Inducing Neutralizing Antibodies in COVID -19 Infected Patients Better Than Vaccine : An Innovative Treatment PHASE2UNKNOWN
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver PHASE2COMPLETED
Effect of Cenicriviroc on HIV Neurocognitive Impairment PHASE2COMPLETED
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer PHASE2NOT_YET_RECRUITING
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) PHASE1RECRUITING
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation PHASE1RECRUITING
Placebo-controlled Assessment of the Effect of a Food Supplement on Skin Protection After Exposure to UV Radiation PHASE1COMPLETED
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer PHASE1COMPLETED
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response nanACTIVE_NOT_RECRUITING
Comparative Study Between Alzheimer's and Multi-infarct Dementia nanUNKNOWN
Evaluation of CCR6 Gene Expression and Circulating CCL20 Levels as Potential Biomarkers in Rheumatoid Arthritis nanNOT_YET_RECRUITING
The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver nanCOMPLETED
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
Value of Various Chemokines in the Detection and Follow up of RCC nanUNKNOWN
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA) nanUNKNOWN
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio) nanCOMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
IL-11 in the Development of Multiple Sclerosis nanUNKNOWN
LoViReT (Low Viral Reservoir Treated Patients) nanCOMPLETED
Lung-Resident Memory Th2 Cells in Asthma nanACTIVE_NOT_RECRUITING
Preliminary Study of CXCL3 As a Biomarker of Diabetic Kidney Disease nanCOMPLETED
Inflammatory Biomarkers in Psychogenic Non-epileptic Seizure nanUNKNOWN
Inflammatory Biomarkers in Seizure nanUNKNOWN
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCR3 binder may also engage these)

ProteinNameSimilarity
Q9BDS8 — 1.000 Q9BDS8 →
P56492 — 1.000 P56492 →
O54814 — 0.996 O54814 →
Q2Y2P0 — 0.996 Q2Y2P0 →
Q9N0Z0 — 0.995 Q9N0Z0 →
CCR1 C-C chemokine receptor type 1 0.994 landscape →
Q2KTE1 — 0.993 Q2KTE1 →
Q95ND1 — 0.993 Q95ND1 →
P56482 — 0.993 P56482 →
Q95NC1 — 0.993 Q95NC1 →
P51676 — 0.993 P51676 →
P35411 — 0.993 P35411 →
O62743 — 0.993 O62743 →
Q9Z2I3 — 0.993 Q9Z2I3 →
O97882 — 0.992 O97882 →
Q95ND2 — 0.992 Q95ND2 →
Q64H34 — 0.992 Q64H34 →
Q95NC9 — 0.992 Q95NC9 →
Q9TV48 — 0.992 Q9TV48 →
P56483 — 0.992 P56483 →
P61815 — 0.992 P61815 →
Q95ND0 — 0.992 Q95ND0 →
Q9TSQ8 — 0.991 Q9TSQ8 →
P56493 — 0.991 P56493 →
Q8HZT9 — 0.991 Q8HZT9 →
Q95NC6 — 0.991 Q95NC6 →
Q95NC2 — 0.991 Q95NC2 →
P61755 — 0.990 P61755 →
Q95NE8 — 0.990 Q95NE8 →
P56439 — 0.990 P56439 →